Landovitz, R. J. et al. Cabotegravir for HIV prevention in cisgender men and transgender women. N. Engl. J. Med. 385, 595–608 (2021).
Grant, R. M. et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N. Engl. J. Med. 363, 2587–2599 (2010).
Joint United Nations Programme on HIV/AIDS. Global HIV and AIDS statistics — 2022 fact sheet. UNAIDS https://www.unaids.org/en/resources/fact-sheet (2022).
Cohen, S. E. et al. Acquisition of tenofovir-susceptible, emtricitabine-resistant HIV despite high adherence to daily pre-exposure prophylaxis: a case report. Lancet HIV https://doi.org/10.1016/S2352-3018(18)30288-1 (2018).
Cohen, S. M., Hu, X., Sweeney, P., Johnson, A. S. & Hall, H. I. HIV viral suppression among persons with varying levels of engagement in HIV medical care, 19 US jurisdictions. J. Acquir. Immune Defic. Syndr. 67, 519–527 (2014).
Havlir, D. V. et al. HIV testing and treatment with the use of a community health approach in rural Africa. N. Engl. J. Med. 381, 219–229 (2019).
Hayes, R. J. et al. Effect of universal testing and treatment on HIV incidence — HPTN 071 (PopART). N. Engl. J. Med. 381, 207–218 (2019).
Makhema, J. et al. Universal testing, expanded treatment, and incidence of HIV infection in Botswana. N. Engl. J. Med. 381, 230–242 (2019).
Cohen, M. S. et al. Prevention of HIV-1 infection with early antiretroviral therapy. N. Engl. J. Med. 365, 493–505 (2011).
Larmarange, J. et al. The impact of population dynamics on the population HIV care cascade: results from the ANRS 12249 Treatment as Prevention trial in rural KwaZulu-Natal (South Africa). J. Int. AIDS Soc. 21, e25128 (2018).
Thigpen, M. C. et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N. Engl. J. Med. 367, 423–434 (2012).
Liu, A. Y. et al. Preexposure prophylaxis for HIV infection integrated with municipal- and community-based sexual health services. JAMA Intern. Med. 176, 75–84 (2016).
Choopanya, K. et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 381, 2083–2090 (2013).
Mayer, K. H. et al. Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial. Lancet 396, 239–254 (2020).
Molina, J. M. et al. On-demand preexposure prophylaxis in men at high risk for HIV-1 Infection. N. Engl. J. Med. 373, 2237–2246 (2015).
World Health Organization. Guidelines on Long-Acting Injectable Cabotegravir for HIV Prevention (WHO, 2022).
Gandhi, R. T. et al. Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2022 recommendations of the International Antiviral Society-USA panel. J. Am. Med. Assoc. 329, 63–84 (2022).
Van Damme, L. et al. Preexposure prophylaxis for HIV infection among African women. N. Engl. J. Med. 367, 411–422 (2012).
Marrazzo, J. M. et al. Tenofovir-based preexposure prophylaxis for HIV infection among African women. N. Engl. J. Med. 372, 509–518 (2015).
Abdool Karim, Q. et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 329, 1168–1174 (2010).
Baeten, J. M. et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N. Engl. J. Med. 367, 399–410 (2012).
Baeten, J. M. et al. Use of a vaginal ring containing dapivirine for HIV-1 prevention in women. N. Engl. J. Med. 375, 2121–2132 (2016).
World Health Organization. WHO recommends the dapivirine vaginal ring as a new choice for HIV prevention for women at substantial risk of HIV infection. WHO https://www.who.int/news/item/26-01-2021-who-recommends-the-dapivirine-vaginal-ring-as-a-new-choice-for-hiv-prevention-for-women-at-substantial-risk-of-hiv-infection (2021).
Baeten, J. M., Hendrix, C. W. & Hillier, S. L. Topical microbicides in HIV prevention: state of the promise. Annu. Rev. Med. 71, 361–377 (2020).
Delany-Moretlwe, S. et al. Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial. Lancet 399, 1779–1789 (2022).
Marzinke, M. A. et al. Characterization of human immunodeficiency virus (HIV) infection in cisgender men and transgender women who have sex with men receiving injectable cabotegravir for HIV prevention: HPTN 083. J. Infect. Dis. 224, 1581–1592 (2021).
Gulick, R. M. et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N. Engl. J. Med. 337, 734–739 (1997).
Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. Clinicalinfo.HIV.gov https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-arv/whats-new (2023).
Trickey, A. et al. Associations of modern initial antiretroviral drug regimens with all-cause mortality in adults with HIV in Europe and North America: a cohort study. Lancet HIV 9, e404–e413 (2022).
Venter, W. D. F. et al. Dolutegravir plus two different prodrugs of tenofovir to treat HIV. N. Engl. J. Med. 381, 803–815 (2019).
Editorial. PEPFAR looks to the future. Lancet HIV 9, e367 (2022).
Orkin, C. et al. Long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label, phase 3 FLAIR study. Lancet HIV 8, e185–e196 (2021).
Christopoulos, K. A. et al. First demonstration project of long-acting injectable antiretroviral therapy for persons with and without detectable HIV viremia in an urban HIV clinic. Clin. Infect. Dis. 76, e645–e651 (2022).
Segal-Maurer, S. et al. Capsid Inhibition with lenacapavir in multidrug-resistant HIV-1 infection. N. Engl. J. Med. 386, 1793–1803 (2022).
Benhabbour, S. R. et al. Ultra-long-acting tunable biodegradable and removable controlled release implants for drug delivery. Nat. Commun. 10, 4324 (2019).
Kovarova, M. et al. Ultra-long-acting removable drug delivery system for HIV treatment and prevention. Nat. Commun. 9, 4156 (2018).
Haynes, B. F., Burton, D. R. & Mascola, J. R. Multiple roles for HIV broadly neutralizing antibodies. Sci. Transl Med. 11, eaaz2686 (2019).
Caskey, M., Klein, F. & Nussenzweig, M. C. Broadly neutralizing anti-HIV-1 monoclonal antibodies in the clinic. Nat. Med. 25, 547–553 (2019).
Gaudinski, M. R. et al. Safety and pharmacokinetics of broadly neutralising human monoclonal antibody VRC07-523LS in healthy adults: a phase 1 dose-escalation clinical trial. Lancet HIV 6, e667–e679 (2019).
Gaudinski, M. R. et al. Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: a phase 1 open-label clinical trial in healthy adults. PLoS Med. 15, e1002493 (2018).
Corey, L. et al. Two randomized trials of neutralizing antibodies to prevent HIV-1 acquisition. N. Engl. J. Med. 384, 1003–1014 (2021).
Sneller, M. C. et al. Combination anti-HIV antibodies provide sustained virological suppression. Nature 606, 375–381 (2022).
Gaebler, C. et al. Prolonged viral suppression with anti-HIV-1 antibody therapy. Nature 606, 368–374 (2022).
Pegu, A. et al. Potent anti-viral activity of a trispecific HIV neutralizing antibody in SHIV-infected monkeys. Cell Rep. 38, 110199 (2022).
Collins, F. et al. The NIH-led research response to COVID-19. Science 379, 441–444 (2023).
Buchbinder, S. P. et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 372, 1881–1893 (2008).
Rerks-Ngarm, S. et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N. Engl. J. Med. 361, 2209–2220 (2009).
Haynes, B. F. et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N. Engl. J. Med. 366, 1275–1286 (2012).
Gray, G. E. et al. Immune correlates of the Thai RV144 HIV vaccine regimen in South Africa. Sci. Transl Med. 11, eaax1880 (2019).
Moodie, Z. et al. Analysis of the HVTN 702 Phase 2b-3 HIV-1 vaccine trial in South Africa assessing RV144 antibody and T-cell correlates of HIV-1 acquisition risk. J. Infect. Dis. 226, 246–257 (2022).
Gray, G. E. et al. Vaccine efficacy of ALVAC-HIV and bivalent subtype C gp120-MF59 in adults. N. Engl. J. Med. 384, 1089–1100 (2021).
Barouch, D. H. et al. Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19). Lancet 392, 232–243 (2018).
Hansen, S. G. et al. Immune clearance of highly pathogenic SIV infection. Nature 502, 100–104 (2013).
Jiang, C. et al. Distinct viral reservoirs in individuals with spontaneous control of HIV-1. Nature 585, 261–267 (2020).
Turk, G. et al. A possible sterilizing cure of HIV-1 infection without stem cell transplantation. Ann. Intern. Med. 175, 95–100 (2022).
Jardine, J. G. et al. HIV-1 broadly neutralizing antibody precursor B cells revealed by germline-targeting immunogen. Science 351, 1458–1463 (2016).
Haynes, B. F. et al. Strategies for HIV-1 vaccines that induce broadly neutralizing antibodies. Nat. Rev. Immunol. 23, 142–158 (2023).
Leggat, D. J. et al. Vaccination induces HIV broadly neutralizing antibody precursors in humans. Science 378, eadd6502 (2022).
Sanders, R. W. et al. A next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies. PLoS Pathog. 9, e1003618 (2013).
Borst, A. J. et al. Germline VRC01 antibody recognition of a modified clade C HIV-1 envelope trimer and a glycosylated HIV-1 gp120 core. eLife 7, e37688 (2018).
Arunachalam, P. S. et al. T cell-inducing vaccine durably prevents mucosal SHIV infection even with lower neutralizing antibody titers. Nat. Med. 26, 932–940 (2020).
McMahan, K. et al. Correlates of protection against SARS-CoV-2 in rhesus macaques. Nature 590, 630–634 (2021).
Ndung’u, T., McCune, J. M. & Deeks, S. G. Why and where an HIV cure is needed and how it might be achieved. Nature 576, 397–405 (2019).
Deeks, S. G. et al. Research priorities for an HIV cure: International AIDS Society global scientific strategy 2021. Nat. Med. 27, 2085–2098 (2021).
Dybul, M. et al. The case for an HIV cure and how to get there. Lancet HIV 8, e51–e58 (2021).
Ho, Y. C. et al. Replication-competent noninduced proviruses in the latent reservoir increase barrier to HIV-1 cure. Cell 155, 540–551 (2013).
Siliciano, J. D. et al. Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat. Med. 9, 727–728 (2003).
Wagner, T. A. et al. HIV latency. Proliferation of cells with HIV integrated into cancer genes contributes to persistent infection. Science 345, 570–573 (2014).
Maldarelli, F. et al. HIV latency. Specific HIV integration sites are linked to clonal expansion and persistence of infected cells. Science 345, 179–183 (2014).
Einkauf, K. B. et al. Parallel analysis of transcription, integration, and sequence of single HIV-1 proviruses. Cell 185, 266–282.e15 (2022).
Cohn, L. B. et al. HIV-1 integration landscape during latent and active infection. Cell 160, 420–432 (2015).
Nixon, C. C. et al. Systemic HIV and SIV latency reversal via non-canonical NF-κB signalling in vivo. Nature 578, 160–165 (2020).
Badley, A. D., Sainski, A., Wightman, F. & Lewin, S. R. Altering cell death pathways as an approach to cure HIV infection. Cell Death Dis. 4, e718 (2013).
Yates, K. B. et al. Epigenetic scars of CD8+ T cell exhaustion persist after cure of chronic infection in humans. Nat. Immunol. 22, 1020–1029 (2021).
Rutishauser, R. L. et al. TCF-1 regulates HIV-specific CD8+ T cell expansion capacity. JCI Insight 6, e136648 (2021).
Mancuso, P. et al. CRISPR based editing of SIV proviral DNA in ART treated non-human primates. Nat. Commun. 11, 6065 (2020).
Kessing, C. F. et al. In vivo suppression of HIV rebound by didehydro-cortistatin A, a “block-and-lock” strategy for HIV-1 treatment. Cell Rep. 21, 600–611 (2017).
Borducchi, E. N. et al. Ad26/MVA therapeutic vaccination with TLR7 stimulation in SIV-infected rhesus monkeys. Nature 540, 284–287 (2016).
Bailon, L. et al. Safety, immunogenicity and effect on viral rebound of HTI vaccines in early treated HIV-1 infection: a randomized, placebo-controlled phase 1 trial. Nat. Med. 28, 2611–2621 (2022).
Nishimura, Y. et al. Early antibody therapy can induce long-lasting immunity to SHIV. Nature 543, 559–563 (2017).
Mendoza, P. et al. Combination therapy with anti-HIV-1 antibodies maintains viral suppression. Nature 561, 479–484 (2018).
Borducchi, E. N. et al. Antibody and TLR7 agonist delay viral rebound in SHIV-infected monkeys. Nature 563, 360–364 (2018).
Niessl, J. et al. Combination anti-HIV-1 antibody therapy is associated with increased virus-specific T cell immunity. Nat. Med. 26, 222–227 (2020).
Gunst, J. D. et al. Early intervention with 3BNC117 and romidepsin at antiretroviral treatment initiation in people with HIV-1: a phase 1b/2a, randomized trial. Nat. Med. 28, 2424–2435 (2022).
Tebas, P. et al. CCR5-edited CD4+ T cells augment HIV-specific immunity to enable post-rebound control of HIV replication. J. Clin. Invest. 131, e144486 (2021).
Gardner, M. R. et al. AAV-expressed eCD4-Ig provides durable protection from multiple SHIV challenges. Nature 519, 87–91 (2015).
Martinez-Navio, J. M. et al. Adeno-associated virus delivery of anti-HIV monoclonal antibodies can drive long-term virologic suppression. Immunity 50, 567–575.e5 (2019).
Casazza, J. P. et al. Safety and tolerability of AAV8 delivery of a broadly neutralizing antibody in adults living with HIV: a phase 1, dose-escalation trial. Nat. Med. 28, 1022–1030 (2022).
Hutter, G. et al. Long-term control of HIV by CCR5 delta32/delta32 stem-cell transplantation. N. Engl. J. Med. 360, 692–698 (2009).
Gupta, R. K. et al. HIV-1 remission following CCR5Δ32/Δ32 haematopoietic stem-cell transplantation. Nature 568, 244–248 (2019).
Okoye, A. A. et al. Early antiretroviral therapy limits SIV reservoir establishment to delay or prevent post-treatment viral rebound. Nat. Med. 24, 1430–1440 (2018).
Henrich, T. J. et al. HIV-1 persistence following extremely early initiation of antiretroviral therapy (ART) during acute HIV-1 infection: an observational study. PLoS Med. 14, e1002417 (2017).
Mitchell, J. L. et al. Plasmacytoid dendritic cells sense HIV replication before detectable viremia following treatment interruption. J. Clin. Invest. 130, 2845–2858 (2020).
Gondim, M. V. P. et al. Heightened resistance to host type 1 interferons characterizes HIV-1 at transmission and after antiretroviral therapy interruption. Sci. Transl Med. 13, eabd8179 (2021).
Prator, C. A. et al. Circulating CD30+CD4+ T cells increase before human immunodeficiency virus rebound after analytical antiretroviral treatment interruption. J. Infect. Dis. 221, 1146–1155 (2020).
Landovitz, R. J. et al. Tail-phase safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in HIV-uninfected adults: a secondary analysis of the HPTN 077 trial. Lancet HIV 7, e472–e481 (2020).
Eshleman, S. H. et al. HIV RNA screening reduces integrase strand transfer inhibitor resistance risk in persons receiving long-acting cabotegravir for HIV prevention. J. Infect. Dis. 226, 2170–2180 (2022).
Beacroft, L. & Hallett, T. B. The potential impact of a “curative intervention” for HIV: a modelling study. Glob. Health Res. Policy 4, 2 (2019).
Lehman, D. A. et al. Risk of drug resistance among persons acquiring HIV within a randomized clinical trial of single- or dual-agent preexposure prophylaxis. J. Infect. Dis. 211, 1211–1218 (2015).
Dube, K. et al. Participant experiences using novel home-based blood collection device for viral load testing in the HIV cure trials with analytical treatment interruptions. HIV Res. Clin. Pract. 23, 76–90 (2022).
Deeks, S. G. et al. Strong cell-mediated immune responses are associated with the maintenance of low-level viremia in antiretroviral-treated individuals with drug-resistant human immunodeficiency virus type 1. J. Infect. Dis. 189, 312–321 (2004).
Bertagnolli, L. N. et al. Autologous IgG antibodies block outgrowth of a substantial but variable fraction of viruses in the latent reservoir for HIV-1. Proc. Natl Acad. Sci. USA 117, 32066–32077 (2020).
Blazkova, J. et al. Distinct mechanisms of long-term virologic control in two HIV-infected individuals after treatment interruption of anti-retroviral therapy. Nat. Med. 27, 1893–1898 (2021).
Jones, R. B. & Walker, B. D. HIV-specific CD8+ T cells and HIV eradication. J. Clin. Invest. 126, 455–463 (2016).
Collins, D. R., Gaiha, G. D. & Walker, B. D. CD8+ T cells in HIV control, cure and prevention. Nat. Rev. Immunol. 20, 471–482 (2020).
Fukazawa, Y. et al. B cell follicle sanctuary permits persistent productive simian immunodeficiency virus infection in elite controllers. Nat. Med. 21, 132–139 (2015).
Imamichi, H. et al. Defective HIV-1 proviruses produce viral proteins. Proc. Natl Acad. Sci. USA 117, 3704–3710 (2020).
Pollack, R. A. et al. Defective HIV-1 proviruses are expressed and can be recognized by cytotoxic T lymphocytes, which shape the proviral landscape. Cell Host Microbe 21, 494–506.e4 (2017).
Gaiha, G. D. et al. Structural topology defines protective CD8+ T cell epitopes in the HIV proteome. Science 364, 480–484 (2019).
Mothe, B. et al. Therapeutic vaccination refocuses T-cell responses towards conserved regions of HIV-1 in early treated individuals (BCN 01 study). eClinicalMedicine 11, 65–80 (2019).
Korber, B. & Fischer, W. T cell-based strategies for HIV-1 vaccines. Hum. Vaccin. Immunother. 16, 713–722 (2020).
Stevenson, E. M. et al. HIV-specific T cell responses reflect substantive in vivo interactions with antigen despite long-term therapy. JCI Insight 6, e142640 (2021).
Stevenson, E. M. et al. SARS CoV-2 mRNA vaccination exposes latent HIV to Nef-specific CD8+ T-cells. Nat. Commun. 13, 4888 (2022).
Duette, G. et al. The HIV-1 proviral landscape reveals that Nef contributes to HIV-1 persistence in effector memory CD4+ T cells. J. Clin. Invest. 132, e154422 (2022).
Collins, D. R. et al. Functional impairment of HIV-specific CD8+ T cells precedes aborted spontaneous control of viremia. Immunity 54, 2372–2384.e7 (2021).
Lewin, S. R. et al. Multi-stakeholder consensus on a target product profile for an HIV cure. Lancet HIV 8, e42–e50 (2021).
Colasanti, J. et al. Continuous retention and viral suppression provide further insights into the HIV care continuum compared to the cross-sectional HIV care cascade. Clin. Infect. Dis. 62, 648–654 (2016).
Joint United Nations Programme on HIV/AIDS. African leaders unite in pledge to end AIDS in children. UNAIDS https://www.unaids.org/en/keywords/children (2023).
Patel, P. et al. Pregnancy outcomes and pharmacokinetics in pregnant women living with HIV exposed to long-acting cabotegravir and rilpivirine in clinical trials. HIV Med. 24, 568–579 (2022).
Penazzato, M. et al. Advancing the prevention and treatment of HIV in children: priorities for research and development. Lancet HIV 9, e658–e666 (2022).
Persaud, D. et al. Absence of detectable HIV-1 viremia after treatment cessation in an infant. N. Engl. J. Med. 369, 1828–1835 (2013).
Violari, A. et al. A child with perinatal HIV infection and long-term sustained virological control following antiretroviral treatment cessation. Nat. Commun. 10, 412 (2019).
Frange, P. et al. HIV-1 virological remission lasting more than 12 years after interruption of early antiretroviral therapy in a perinatally infected teenager enrolled in the French ANRS EPF-CO10 paediatric cohort: a case report. Lancet HIV 3, e49–54 (2016).
Hartana, C. A. et al. Immune correlates of HIV-1 reservoir cell decline in early-treated infants. Cell Rep. 40, 111126 (2022).
Uprety, P. et al. Human immunodeficiency virus type 1 DNA decay dynamics with early, long-term virologic control of perinatal infection. Clin. Infect. Dis. 64, 1471–1478 (2017).
Capparelli, E. V. et al. Safety and pharmacokinetics of intravenous 10-1074 and VRC01LS in young children. J. Acquir. Immune Defic. Syndr. 91, 182–188 (2022).
Bonacci, R. A., Smith, D. K. & Ojikutu, B. O. Toward greater pre-exposure prophylaxis equity: increasing provision and uptake for black and Hispanic/Latino individuals in the US. Am. J. Prev. Med. 61, S60–S72 (2021).
Harris, N. S. et al. Vital signs: status of human immunodeficiency virus testing, viral suppression, and HIV preexposure prophylaxis — United States, 2013–2018. MMWR Morb. Mortal. Wkly. Rep. 68, 1117–1123 (2019).
Xavier Hall, C. D., Feinstein, B. A., Rusie, L., Phillips Ii, G. & Beach, L. B. Race and sexual identity differences in PrEP continuum outcomes among Latino men in a large Chicago area healthcare network. AIDS Behav. 26, 1943–1955 (2022).
Monroe, A. K. et al. Integrase inhibitor prescribing disparities in the DC and Johns Hopkins HIV cohorts. Open Forum Infect. Dis. 8, ofab338 (2021).
Joint United Nations Programme on HIV/AIDS. In danger: UNAIDS global AIDS update 2022 (UNAIDS, 2022).
Yukl, S. A. et al. Challenges in detecting HIV persistence during potentially curative interventions: a study of the Berlin Patient. PLoS Pathog. 9, e1003347 (2013).
Jensen, B.-E. O. et al. In-depth virological and immunological characterization of HIV-1 cure after CCR5Δ32/Δ32 allogeneic hematopoietic stem cell transplantation. Nat. Med. 29, 583–587 (2023).
Hsu, J. et al. HIV-1 remission and possible cure in a woman after haplo-cord blood transplant. Cell 186, 1115–1126.e8 (2023).
Mendoza, D. et al. Comprehensive analysis of unique cases with extraordinary control over HIV replication. Blood 119, 4645–4655 (2012).
Saez-Cirion, A. et al. Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study. PLoS Pathog. 9, e1003211 (2013).